Home›Screener›GLUE›Profile
D
39/100

Monte Rosa Therapeutics

GLUEProtein Degradation
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Monte Rosa Therapeutics (GLUE) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 2[1], 2 Phase 1[2].

GLUE has 2 Form 4 insider filings recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR · 0001826457 (2026-04-11) ↗
🔬
Clinical Trials
2
NCT05546268NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07119125Healthy Volunteers, Elevated CRP
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
2 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Protein Degradation)
NRIXNurix Therapeutics
D
KYMRKymera Therapeutics
D
ARVNArvinas Inc
F
Data Provenance
cik1 verified
clinical trial2 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR